23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia vs Aima Diagnostics

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia
by 23andMe
VS
Aima Diagnostics
by Aima Diagnostics

AI Verdict

23andMe's tool focuses on providing direct-to-consumer genetic risk information for hereditary thrombophilia through saliva-based DNA testing. Aima Diagnostics, conversely, offers AI-powered interpretation of a broader range of blood test results for early disease detection and personalized insights, primarily targeting healthcare providers and clinics. While both aim to provide health insights through lab analysis, their methodologies (genetics vs. blood biomarkers) and primary target users differ significantly.

Choose 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia if…

Choose 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia if you are an individual of European descent looking for direct-to-consumer genetic insights into your predisposition for developing harmful blood clots. This test identifies specific genetic variants (Factor V Leiden and Prothrombin G20210A) to help you understand your genetic risk and facilitate proactive health discussions with healthcare professionals. It is particularly useful for those who are asymptomatic and may not be aware of their risk without genetic testing.

View 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia →

Choose Aima Diagnostics if…

Choose Aima Diagnostics if you are a healthcare provider, clinic, or laboratory seeking AI-powered, personalized interpretation of complex blood test results. This tool excels at analyzing biomarkers within individual contexts, identifying hidden patterns, long-term trends, and potential risk signals that might be missed by traditional methods. It is ideal for early disease detection, supporting clinical decision-making, and providing more detailed, contextualized patient reports.

View Aima Diagnostics →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia Aima Diagnostics
Pricing $199 Unknown
Deployment Cloud-based (for data access and reports), At-home kit (for sample collection) Cloud-based, API integration, or selective AI testing.
BAA Available No AI-estimated Unknown
FDA Status 1 AI-estimated Unknown
HIPAA No AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia

23andMe offers a direct-to-consumer model with an at-home saliva collection kit and personalized online reports, making it highly accessible and user-friendly for individuals. Aima Diagnostics, while offering personalized insights, is primarily geared towards clinics and laboratories, suggesting a more complex integration and less direct individual usability.

Clinical Value

Tie

Both tools offer significant clinical value in their respective domains. 23andMe provides FDA-cleared genetic health risk information for hereditary thrombophilia, empowering individuals with proactive health insights. Aima Diagnostics offers AI-powered personalized interpretation of blood test results for early disease detection and informed decisions for healthcare professionals, enhancing diagnostic accuracy and understanding of a patient's true condition.

Pricing & Value

23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia

23andMe has transparent, publicly available pricing for its various services, starting at $99 for ancestry and $199 for health + ancestry. Aima Diagnostics does not publicly disclose its pricing, stating it offers different plans for clinics and laboratories, making it difficult to assess its value proposition without direct inquiry.

Enterprise Readiness

Aima Diagnostics

Aima Diagnostics is designed for laboratories and clinics, offering API integration and compliance with HIPAA and GDPR, indicating a strong focus on enterprise-level deployment and data security. 23andMe, while a large company, operates primarily as a direct-to-consumer service and explicitly states it is not HIPAA compliant and not intended for medical diagnosis or insurance reimbursement.

Innovation

Aima Diagnostics

Aima Diagnostics leverages advanced AI and machine learning for personalized, contextual interpretation of blood tests, including early disease detection and advanced liquid biopsy technology for cancer. 23andMe, while a pioneer in direct-to-consumer genetics, focuses on detecting specific, known genetic variants for risk assessment.

Support & Docs

Tie

Both companies provide support and documentation. 23andMe offers educational resources for healthcare professionals and customer care. Aima Diagnostics emphasizes continuous model refinement in collaboration with clinical experts and provides detailed reports with explanations for biomarkers and personalized recommendations.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia Aima Diagnostics
Name 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia Aima Diagnostics
Company 23andMe Aima Diagnostics
Description The 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia is an FDA-cleared direct-to-consumer genetic test that identifies specific genetic variants (Factor V Leiden and Prothrombin G20210A) associated with an increased risk of developing harmful blood clots. It provides personal genetic insights for proactive health discussions with healthcare professionals. Aima Diagnostics provides AI-powered personalized interpretation of blood test results for individuals, physicians, and clinics, analyzing biomarkers within individual contexts for early disease detection and informed decisions.
Categories Clinical Decision Support & Reference, Lab & Diagnostics Clinical Decision Support & Reference, Lab & Diagnostics, Oncology AI
Specialties Hematology, Laboratory Medicine Cardiology, Endocrinology, Family Medicine, Gastroenterology, Internal Medicine, Oncology
Key Features Detection of Factor V Leiden variant (F5 gene), Detection of Prothrombin G20210A variant (F2 gene), Direct-to-consumer saliva sample collection, Personalized online genetic health risk reports, Access to ancestry reports and DNA relative finder, Educational resources for healthcare professionals, Optional participation in genetic research AI-powered biomarker analysis, Personalized health insights, Early disease detection, Contextual interpretation of blood tests, Support for physicians and clinics, Advanced liquid biopsy technology

Videos

Demos, reviews, and walkthroughs featuring 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia and Aima Diagnostics.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

23andMe's Hereditary Thrombophilia test is a direct-to-consumer product, meaning patients order the kit and collect samples at home, then receive online reports. Physicians would primarily interact with the results when patients bring them in for discussion, requiring the physician to interpret the report in a clinical context. Aima Diagnostics, on the other hand, is designed to integrate into clinical workflows for laboratories and clinics, providing AI-powered interpretation of blood test results. This aims to automate routine tasks and improve efficiency, suggesting a more direct integration into a physician's diagnostic process. The learning curve for 23andMe would involve understanding the scope and limitations of their genetic reports, while Aima Diagnostics would require familiarization with its AI-driven insights and how they augment clinical decision-making.
23andMe's service is direct-to-consumer, and its reports are provided to the individual in an online account. Therefore, direct EHR integration would likely involve manual input or patient-initiated sharing of their genetic reports with their physician. Aima Diagnostics offers API integration for clinics and laboratories, suggesting a more seamless and automated flow of AI-powered blood test interpretations directly into existing internal systems, including potentially EHRs.
The 23andMe Hereditary Thrombophilia test has shown >99% agreement with sequencing results in method comparison studies for detecting Factor V Leiden and Prothrombin G20210A variants. However, it's important to note that it does not detect all genetic variants related to hereditary thrombophilia and is most relevant for people of European descent. Aima Diagnostics claims that personalization significantly enhances the accuracy of blood diagnostics by 10-30%, with potential growth to 40%, by accounting for individual factors and analyzing relationships between biomarkers. Their algorithms are trained on millions of laboratory records, and every report undergoes verification to ensure compliance with medical standards.
23andMe's Hereditary Thrombophilia test is primarily relevant for specialties like Hematology and Laboratory Medicine, as it focuses on specific genetic variants associated with an increased risk of blood clots. Aima Diagnostics, with its AI-powered personalized interpretation of general blood test results, has a broader specialty fit, including Cardiology, Endocrinology, Family Medicine, Gastroenterology, Internal Medicine, and Oncology, by providing insights for early disease detection and informed decisions across various biomarkers.
For 23andMe, as a direct-to-consumer service, the primary audit trail would likely be the individual's access to their online reports and any sharing history they initiate. For Aima Diagnostics, robust audit-trail features are a key component of their system. They state that all access and changes must be logged with immutable audit trails, retained for a minimum of 10 years, and that their systems comply with GDPR and HIPAA. This includes tracking salient input features, confidence intervals, decision traceability via explainable AI (XAI) methodology, and stratified performance audits across various demographic groups.
23andMe's direct-to-consumer model means that multi-site rollout for a health system would involve educating patients and physicians on how to utilize and interpret the individual reports. Aima Diagnostics is designed for integration with laboratories and clinics, offering API integration or selective AI testing, which suggests a more structured approach to multi-site deployment. Their cloud-based deployment and API availability indicate a design for scalability across multiple clinical sites or health systems.
The 23andMe Hereditary Thrombophilia report provides personal genetic insights regarding Factor V Leiden and Prothrombin G20210A variants, which can inform proactive health discussions with healthcare professionals. However, it explicitly states that it does not describe a person's overall risk of developing harmful blood clots and should be used along with other clinical information. Aima Diagnostics provides AI-powered personalized interpretation of a broader range of blood test results, analyzing biomarkers within individual contexts for early disease detection and informed decisions. This includes contextual modeling of lifestyle and environmental factors, integration of biological variation, and ancestry-informed models, aiming to provide a more comprehensive clinical picture beyond standard reference ranges.

More Comparisons

eCARTv5 Clinical Deterioration Suite (“eCART”) vs Google Med-PaLM 2
ChatGPT vs Google Med-PaLM 2
When choosing between ChatGPT and Google Med-PaLM 2, physicians should consider their primary use case and desired level of medical…
Brainomix 360 e-CTA vs Google Med-PaLM 2
DeepXray vs Google Med-PaLM 2

More matchups featuring 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia or Aima Diagnostics

Backers

Who funded each tool's parent company.

23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia

AI Tool Finder
AI-powered search. Results may not be comprehensive.